February 15, 2021 – ADM Diagnostics (ADMdx) has published its findings from a study of the drug rasagiline in patients with Alzheimer’s disease. ADMdx performed the image analysis for this study, which was led by Dr. Jeffrey Cummings of the Lou Ruvo Center for Brain Health, Cleveland Clinic. ADMdx applied methods of measuring changes in brain activity measured using PET imaging of glucose metabolism. The analyses revealed a treatment effect consistent with the monoamine inhibition properties of rasagiline. ADMdx also applied machine learning classification software to confirm the likelihood of Alzheimer’s disease in the study participants. Results matched the tau burden that was observed in these patients, measured using tau PET.